 |
|
|
| |
Prevention of Liver-Related Complications With Elbasvir/Grazoprevir in Hepatitis C Infected Patients Who Are Receiving Opioid Agonist Therapy (OAT)
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Shelby Corman1; Yiling Jiang2; Heather Loryn Platt3;Chizoba Nwankwo3
1Pharmerit International, Bethesda, MD, USA; 2Merck, Sharp & Dohme Limited, Hoddesdon, Hertfordshire, UK; 3Merck & Co., Inc., Kenilworth, NJ, USA
C-EDGE CO-STAR: Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy.....http://www.natap.org/2016/EASL/EASL_107.htm
|
| |
|
|
|
|
|
